Related Blog Posts from the Wikinvest Wire

AngioDynamics (ANGO)   Subscribe to AngioDynamics (ANGO) content from the Wikinvest Wire
 » Back to AngioDynamics (NASDAQ:ANGO) Stock Page

  

4/10/11(ANGO) AngioDynamics Unveils New DuraMax Catheter (Stock Blog Hub)

Therapeutic and diagnostic devices maker AngioDynamics (ANGO) has unveiled its new DuraMax stepped-tip chronic dialysis catheter in the U.S. The Queensbury, New York-based company has also launched the DuraMaxVP (VascPak) component kit designed for outpatient vascular access centers. AngioDynamics has begun shipping the DuraMax catheter, which leverages its proprietary Curved Tip catheter technology. The next generation [...]

10/8/10AngioDynamics Revises FY11 Guidance Down (Benzinga)

AngioDynamics (NASDAQ: ANGO) F1Q11 in line with EPS preannouncement of $0.08. The company guided to this range versus the then Consensus estimate of $0.10. AngioDynamics revised full year F2011 guidance down to $0.47-$0.50 from $0.53-$0.56, which assumes organic sales growth of 2% to 4%. Net sales of $51.5m were up 3% and in line with the preannouncement, but were below the company initial expectations. Management attributed the weakness to realignment in the vascular sales force, as...

10/7/10AngioDynamics Inc. Misses Estimates (ANGO) (Benzinga)

AngioDynamics Inc. (NASDAQ: ANGO) reports Q3 earnings of $0.08 versus consensus of $0.14. AngioDynamics Inc. reports revenues of $51.5 million versus consensus of $107.93 million. ANGO issued the following guidance: Net sales in the range of $220.0 million to $225.0 million, an increase of 2% to 4% over fiscal 2010 net sales Gross margin in the range of 58% to 59% of net sales GAAP operating income in the range of $20.5 million to $22.0 million EBITDA in the range of $33.0 million to...

10/7/10AngioDynamics Updates 2011 Guidance (Benzinga)

AngioDynamics (NASDAQ: ANGO) updates guidance: Fiscal 2011 Guidance The Company updated its outlook for fiscal 2011 as follows: ~Net sales in the range of $220.0 million to $225.0 million, an increase of 2% to 4% over fiscal 2010 net sales ~Gross margin in the range of 58% to 59% of net sales ~GAAP operating income in the range of $20.5 million to $22.0 million ~EBITDA in the range of $33.0 million to $34.5 million ~GAAP EPS in the range of $0.47 to $0.50, inclusive of a $0.21 to...

10/7/10Earnings Scheduled For October 7 (PEP, MU, AA, ANGO, DRWI, ISCA, SNVNF, NUHC) (Benzinga)

PepsiCo (NYSE: PEP) is expected to post its Q3 EPS at $1.21. Micron Technology Inc (NASDAQ: MU) may report its Q4 earnings at $0.40 per share. Alcoa Inc (NYSE: AA) is estimated to post its earnings at $0.07 in the third-quarter. AngioDynamics Inc (NASDAQ: ANGO) may post its Q1 earnings at $0.08 per share. Dragonwave Inc (NASDAQ: DRWI) may report its Q2 earnings at $0.02 per share. International Speedway Corp (NASDAQ: ISCA) is expected to post its Q3 EPS at $0.28. Sandvine...

9/16/10(ANGO) AngioDynamics Improves VenaCure Laser Vein Treatment (Stock Blog Hub)

Therapeutic and diagnostic devices maker AngioDynamics Inc. (ANGO) has expanded its VenaCure EVLT laser vein treatment with the launch of a new access kit, which will reduce both procedure time and steps for physicians using VenaCure’s NeverTouch laser fiber to treat varicose veins (abnormally swollen veins), a condition affecting more than 40 million Americans annually. The [...]

5/17/10(ANGO) AngioDynamics Analyst Maintains Neutral Rating (Stock Blog Hub)

We recently reiterated our ‘Neutral’ rating on AngioDynamics Inc. (ANGO) with a target price of $17 based on a P/E of 29.8x our fiscal 2011 EPS estimate of 57 cents. The company’s results for the third quarter fiscal 2010 were mixed. In the third quarter, AngioDynamics reported earnings per share of 13 cents, higher than the [...]

5/11/10(ANGO) AngioDynamics Announces New Product (Stock Blog Hub)

AngioDynamics, Inc. (ANGO) recently launched its new product, Centros hemodialysis access catheter, in the United States. The new product uses a curved tip catheter technology and provides higher blood flow and lower recirculation. It has been tested that when Centros is placed in the lower portion of the superior vena cava, the curved tip of the [...]

4/1/10(ANGO) AngioDynamics Beats Consensus Estimates (Stock Blog Hub)

AngioDynamics, Inc. (ANGO) recently reported third quarter fiscal 2010 earnings per share of 13 cents that beat the Zacks Consensus Estimate of 12 cents and the year-ago earnings of 8 cents. Sales Total revenues in the third quarter increased 6% year over year to $52.2 million. Peripheral Vascular sales increased 8% year over year to $22.4 million. [...]

1/6/10(ANGO) AngioDynamics Beats Estimates (Stock Blog Hub)

AngioDynamics, Inc. (ANGO) reported second quarter fiscal 2010 earnings per share of 13 cents, beating the Zacks Consensus Estimate of 11 cents and the year-ago earnings of 12 cents. The company also reported an expansion in its top-line and raised the sales outlook for the entire year. Sales Net sales in the second quarter increased 10% year [...]

1/5/10(ANGO) AngioDynamics Launches Two New Products (Stock Blog Hub)

Recently, AngioDynamics (ANGO) expanded its product portfolio by launching two products ? the total abscession nephrostomy drainage catheter and the micro-introducer kits with a new stiffened introducer option. AngioDynamics completed the total abscession family of products by launching the nephrostomy drainage catheter.  The family of products, inclusive of general drains and a biliary drainage catheter, provides [...]

10/8/09(ANGO) AngioDynamics Outperforms Estimates (Stock Blog Hub)

AngioDynamics, Inc. (ANGO) yesterday reported first quarter fiscal 2010 earnings per share of 9 cents, surpassing the Zacks Consensus Estimate of 8 cents. Earnings per share in the year-ago quarter also reached 9 cents. Sales Net sales in the reported quarter were $50.1 million, increasing 13% year over year. The increase was across all the business segments. [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki